Please use this identifier to cite or link to this item:
Title: Multisite Assessment of Aging-Related Tau Astrogliopathy (ARTAG)
Author: Kovacs, Gabor G.
Xie, Sharon X.
Lee, Edward B.
Robinson, John L.
Caswell, Carrie
Irwin, David J.
Toledo, Jon B.
Johnson. Victoria E.
Smith, Douglas H.
Alafuzoff, Irina
Attems, Johannes
Bencze, Janos
Bieniek, Kevin F.
Bigio, Eileen H.
Bodi, Istvan
Budka, Herbert
Dickson, Dennis W.
Dugger, Brittany N.
Duyckaerts, Charles
Ferrer, Isidro (Ferrer Abizanda)
Forrest, Shelley L.
Gelpi, Ellen
Gentleman, Stephen M.
Giaccone, Giorgio
Grinberg, Lea T.
Halliday, Glenda M.
Hatanpaa, Kimmo J.
Hof, Patrick R.
Hofer, Monika
Hortobágyi, Tibor
Ironside, James W.
King, Andrew
Kofler, Julia
Kövari, Enikö
Kril, Jillian J.
Love, Seth
Mackenzie, Ian R.
Mao, Qinwen
Matej, Radoslav
McLean, Catriona
Keywords: Envelliment cerebral
Malalties neurodegeneratives
Aging brain
Neurodegenerative Diseases
Issue Date: 2017
Publisher: Lippincott, Williams & Wilkins. Wolters Kluwer Health
Abstract: Aging-related tau astrogliopathy (ARTAG) is a recently introduced terminology. To facilitate the consistent identification of ARTAG and to distinguish it from astroglial tau pathologies observed in the primary frontotemporal lobar degeneration tauopathies we evaluated how consistently neuropathologists recognize (1) different astroglial tau immunoreactivities, including those of ARTAG and those associated with primary tauopathies (Study 1); (2) ARTAG types (Study 2A); and (3) ARTAG severity (Study 2B). Microphotographs and scanned sections immunostained for phosphorylated tau (AT8) were made available for download and preview. Percentage of agreement and kappa values with 95% confidence interval (CI) were calculated for each evaluation. The overall agreement for Study 1 was>60% with a kappa value of 0.55 (95% CI 0.433-0.645). Moderate agreement (>90%, kappa 0.48, 95% CI 0.457-0.900) was reached in Study 2A for the identification of ARTAG pathology for each ARTAG subtype (kappa 0.37-0.72), whereas fair agreement (kappa 0.40, 95% CI 0.341-0.445) was reached for the evaluation of ARTAG severity. The overall assessment of ARTAG showed moderate agreement (kappa 0.60, 95% CI 0.534-0.653) among raters. Our study supports the application of the current harmonized evaluation strategy for ARTAG with a slight modification of the evaluation of its severity.
Note: Versió postprint del document publicat a:
It is part of: Journal of Neuropathology and Experimental Neurology, 2017, vol. 76, p. 605-619
Related resource:
ISSN: 0022-3069
Appears in Collections:Articles publicats en revistes (Patologia i Terapèutica Experimental)

Files in This Item:
File Description SizeFormat 
689427.pdf2.74 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.